title: Nuclear factor-kappaB modulation in patients undergoing induction chemotherapy for acute myelogenous leukemia.
abstract: OBJECTIVE
  Nuclear factor-kappaB (NF-kappaB) is constitutively expressed in many acute myelogenous leukemia (AML) cells and AML stem cells. Ex vivo treatment of AML cells with inhibitors of NF-kappaB results in diminished AML cell survival and enhances the cytotoxic effects of chemotherapeutic agents. The purpose of this study was to determine if standard anti-inflammatory agents modulate AML cell nuclear NF-kappaB when administered in conjunction with induction chemotherapy.
  
  
  METHODS
  Patients with newly diagnosed AML were treated with dexamethasone, choline magnesium trisalicylate, or both for 24 hours prior to and 24 hours following initiation of standard induction chemotherapy. AML cell nuclear NF-kappaB was measured at baseline, 24, and 48 hours.
  
  
  RESULTS
  Choline magnesium trisalicylate +/- dexamethasone decreased nuclear NF-kappaB, whereas dexamethasone alone was associated with an increase in nuclear NF-kappaB in AML cells.
  
  
  CONCLUSIONS
  These results show the feasibility of NF-kappaB modulation in conjunction with induction chemotherapy for patients with AML using inexpensive readily available medications. A follow-up study to determine the effects of NF-kappaB modulation on clinical end points is warranted.
authors.affiliation: Division of Medical Oncology, The Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA. strairrk@umdnj.edu
authors.forename: Roger K
authors.initials: RK
authors.lastname: Strair
authors.forename: Mecide
authors.initials: M
authors.lastname: Gharibo
authors.forename: Dale
authors.initials: D
authors.lastname: Schaar
authors.forename: Arnold
authors.initials: A
authors.lastname: Rubin
authors.forename: Jonathan
authors.initials: J
authors.lastname: Harrison
authors.forename: Joseph
authors.initials: J
authors.lastname: Aisner
authors.forename: Hsin-Ching
authors.initials: HC
authors.lastname: Lin
authors.forename: Yong
authors.initials: Y
authors.lastname: Lin
authors.forename: Lauri
authors.initials: L
authors.lastname: Goodell
authors.forename: Monika
authors.initials: M
authors.lastname: Anand
authors.forename: Binaifer
authors.initials: B
authors.lastname: Balsara
authors.forename: Liesel
authors.initials: L
authors.lastname: Dudek
authors.forename: Arnold
authors.initials: A
authors.lastname: Rabson
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Medina
mesh_terms: D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002467:Cell Nucleus / Q000187:drug effects / Q000378:metabolism; D002794:Choline / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003907:Dexamethasone / Q000008:administration & dosage*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016328:NF-kappa B / Q000096:biosynthesis* / Q000187:drug effects; D012459:Salicylates / Q000008:administration & dosage*
chemical_list: D000893:Anti-Inflammatory Agents; D016328:NF-kappa B; D012459:Salicylates; D003907:Dexamethasone; C017959:choline magnesium trisalicylate; D002794:Choline